Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
We will evaluate the feasibility, toxicity, and effectiveness of combination chemotherapy
(paclitaxel/carboplatin)plus combination targeted therapy (bevacizumab/erlotinib)in the first
line treatment of patients with carcinoma of unknown primary site. There is limited
experience with either bevacizumab or erlotinib in the treatment of cancers of unknown site
but given the heterogeneous nature of the tumor, it is likely that inhibition of angiogenesis
pathways and/or the EGFR pathway are effective strategies in at least a proportion.